



Society for Cardiac Robotic Navigation to Showcase Stereotaxis Clinical Value & Technology

July 31, 2019

ST. LOUIS, July 31, 2019 (GLOBE NEWSWIRE) -- [Stereotaxis](#) (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will participate in the [Society for Cardiac Robotic Navigation's 4th Annual Meeting](#), which will take place September 5-6 in Nice, France.

The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of remote technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals interested in advancing robotics to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. SCRN has grown substantially in recent years and this year's conference will include over 30 faculty and nearly 100 registered attendees from over 20 countries.

Presentations and events at the SCRN 2019 annual meeting that will feature Stereotaxis technology include the following:

- Live robotic cardiac ablation procedure integrated with Acutus' mapping technology
- Presentation on robotic cardiac ablation procedures combined with non-invasive preoperative mapping
- Update on Stereotaxis' prospective randomized trial to demonstrate superiority of robotic cardiac ablation over manual cardiac ablation in ventricular tachycardia
- Update on Stereotaxis' study on epicardial ablation using robotic navigation
- Various discussions on the use of Stereotaxis robotic technology to effectively, safely, and efficiently treat a broad range of arrhythmias including atrial fibrillation, atrial flutter, premature ventricular contractions, and ventricular tachycardia
- Introduction to Stereotaxis' novel robotic system: Genesis RMN System
- Presentation on fluoroless cardiac ablation procedures facilitated by Stereotaxis technology
- Presentation on the digitization of surgery and ability of Stereotaxis technology to support remote procedures

David Fischel, Chairman and CEO of Stereotaxis, commented, "We are excited to see the growth of SCRN into a strong, dynamic, physician society. It reflects the growing global enthusiasm for robotics and the increasing body of clinical literature demonstrating the benefits of our technology for arrhythmia patients, physicians and providers. We look forward to engaging with the attendees at SCRN who share our passion for improving electrophysiology with robotics."

About Stereotaxis

[Stereotaxis](#) is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. Stereotaxis' robotic technology has received various regulatory clearances in the United States, European Union, Japan, Canada, China, and elsewhere. The Stereotaxis Genesis RMN System is CE marked and will become available in other global geographies subject to regulatory approvals. Stereotaxis Imaging Model S is CE marked and FDA cleared. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contacts:

David L. Fischel
Chairman and Chief Executive Officer

Martin C. Stammer
Chief Financial Officer

314-678-6100
investors@stereotaxis.com



Source: Stereotaxis, Inc.